Congenital Heart Disease Requiring Maintenance of Ductus Arteriosus in Critically Ill Newborns Admitted at A Tertiary Neonatal Intensive Care Unit

1. Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol. 2002;39:1890–900.10.1016/S0735-1097(02)01886-7Search in Google Scholar

2. Oster ME, Lee KA, Honein MA, Riehle-Colarusso T, Shin M, Correa A. Temporal trends in survival among infants with critical congenital heart defects. Pediatrics. 2013;131:e1502-8. doi: 10.1542/peds.2012-3435.10.1542/peds.2012-3435Search in Google Scholar

3. Reller MD, Strickland MJ, Riehle-Colarusso T, Mahle WT, Correa A. Prevalence of congenital heart defects in metropolitan Atlanta, 1998-2005. J Pediatr. 2008;153:807-13. doi: 10.1016/j.jpeds.2008.05.05910.1016/j.jpeds.2008.05.059Search in Google Scholar

4. Yun SW. Congenital heart disease in the newborn requiring early intervention. Korean J Pediatr. 2011;54:183–91. doi: 10.3345/kjp.2011.54.5.18310.3345/kjp.2011.54.5.183Search in Google Scholar

5. Olney RS, Ailes EC, Sontag MK. Detection of critical congenital heart defects: Review of contributions from prenatal and newborn screening. Semin Perinatol. 2015;39:230-7. doi: 10.1053/j.semperi.2015.03.007.10.1053/j.semperi.2015.03.007Search in Google Scholar

6. American Institute of Ultrasound in Medicine. AIUM practice guideline for the performance of an antepartum obstetric ultrasound examination. J Ultrasound Med. 2003;22:1116–25.10.7863/jum.2003.22.10.1116Search in Google Scholar

7. AIUM practice guideline for the performance of obstetric ultrasound examinations. J Ultrasound Med. 2010;29:157–66.10.7863/jum.2010.29.1.157Search in Google Scholar

8. Momma K, Uemura S, Nishihara S, Ota Y. Dilatation of the ductus arteriosus by prostaglandins and prostaglandin’s precursors. Pediatr Res. 1980;14:1074-7. DOI: 10.1203/00006450-198009000-0001110.1203/00006450-198009000-00011Search in Google Scholar

9. Heymann MA, Rudolph AM. Ductus arteriosus dilatation by prostaglandin E1 in infants with pulmonary atresia. Pediatrics. 1977;59:325-9.10.1542/peds.59.3.325Search in Google Scholar

10. Benson LN, Olley PM, Patel RG, Coceani F, Rowe RD. Role of prostaglandin E1 infusion in the management of transposition of the great arteries. Am J Cardiol.1979;44:691–6.10.1016/0002-9149(79)90289-3Search in Google Scholar

11. Hundalani SG, Kulkarni M, Fernandes CJ, Cabrera AG, Shivanna B, Pammi M. Prostaglandin E1 for maintaining ductal patency in neonates with ductus-dependent cardiac lesions (Protocol). Cochrane Database of Systematic Reviews. 2014;12:CD011417. DOI: 10.1002/14651858.CD011417.10.1002/14651858.CD011417Search in Google Scholar

12. Kobayashi T, Narumiya S. Function of prostanoid receptors: studies on knockout mice. Prostaglandins Other Lipid Mediat. 2002;68-69:557-73.10.1016/S0090-6980(02)00055-2Search in Google Scholar

13. Reese J, Veldman A, Shah L, Vucovich M, Cotton RB. Inadvertent relaxation of the ductus arteriosus by pharmacologic agents that are commonly used in the neonatal period. Semin Perinatol. 2010;34:222-30. doi: 10.1053/j.semperi.2010.02.007.10.1053/j.semperi.2010.02.007Search in Google Scholar

14. Buck ML. Prostaglandin E1 treatment of congenital heart disease: use prior to neonatal transport. DICP. 1991;25:408-9.10.1177/106002809102500413Search in Google Scholar

15. Moldovan E, Cucerea M. Drug Closure of a Patent Ductus Arteriosus in An Extremely Low Birth Weight Premature Newborn. A Case Report. J Crit Care Med. 2015;1:28-32. DOI: 10.1515/jccm-2015-000610.1515/jccm-2015-0006Search in Google Scholar

16. Dolbec K. Congenital heart disease. Emerg Med Clin North Am. 2011;29:811-27. doi: 10.1016/j.emc.2011.08.005.10.1016/j.emc.2011.08.005Search in Google Scholar

17. Yaffe SJ, Aranda JV. Neonatal and Pediatric Pharmacology 4e: Therapeutic Principles In Practice. Lippincott Williams & Wilkins, Philadelphia, PA. 2011.Search in Google Scholar

18. Toganel R. Critical Congenital Heart Diseases as Lifethreatening Conditions in the Emergency Room. Journal of Cardiovascular Emergencies. 2016;2:7-10. DOI: 10.1515/jce-2016-0002.10.1515/jce-2016-0002Search in Google Scholar

19. Chamberlin M, Lozynski J. To go against nature: manipulating the neonatal ductusarteriosus with prostaglandin. Newborn and Infant Nursing Reviews. 2006;6:158-62. DOI: 10.1053/j.nainr.2006.05.001.10.1053/j.nainr.2006.05.001Search in Google Scholar

20. Elliott RB, Starling MB, Neutze JM. Medical manipulation of the ductus arteriosus. Lancet.1975;1:140e2.10.1016/S0140-6736(75)91432-4Search in Google Scholar

21. Nelson textbook of paediatrics. Arch Dis Child 1983;58:942.Search in Google Scholar

22. Olley PM, Coceani F, Bodach E. E-type prostaglandins: a new emergency therapy for certain cyanotic congenital heart malformations. Circulation.1976;53:728 e31.http://dx.doi.org/10.1161/01.CIR.53.4.728Search in Google Scholar

23. Heymann MA, Rudolph AM. Ductus arteriosus dilatation by prostaglandin E1 in infants with pulmonary atresia. Pediatrics.1977;59:325e9.10.1542/peds.59.3.325Search in Google Scholar

24. Huang FK, Lin CC, Huang TC, et al. Reappraisal of the prostaglandin E1 dose for early newborns with patent ductus arteriosus-dependent pulmonary circulation. Pediatr Neonatol. 2013;54:102-6. doi: 10.1016/j.pedneo.2012.10.007.10.1016/j.pedneo.2012.10.00723590954Search in Google Scholar

25. Talosi G, Katona M, Túri S. Side-effects of long-term prostaglandin E(1) treatment in neonates. Pediatr Int. 2007;49:335-40. DOI: 10.1111/j.1442-200X.2007.02380.x10.1111/j.1442-200X.2007.02380.x17532831Search in Google Scholar

26. Middleton P, Kelly AM, Brown J, Robertson M. Agreement between arterial and central venous values for pH, bicarbonate, base excess, and lactate. Emerg Med J. 2006;23:622-4. DOI: 10.1136/emj.2006.03591510.1136/emj.2006.035915256416516858095Search in Google Scholar